Physician profile
Marina Neystat
NPI 1124013990
$27,214.24
in general payments reported to CMS, 2019-2025
74 companies · $3,468 in 2025
The $3,468 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,183 · 2020: $3,331 · 2021: $4,366 · 2022: $4,606 · 2023: $3,911 · 2024: $4,349 · 2025: $3,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $3.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,724.68 |
| Education | $3.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,016.98 | 2021-2025 | |
| Amgen INC. | $1,456.14 | 2019-2025 | Uplizna, Aimovig |
| Ucb, INC. | $1,427.61 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Sk Life Science, INC. | $1,288.88 | 2020-2025 | Xcopri |
| Biogen, INC. | $1,254.35 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Genentech USA, INC. | $1,222.49 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Allergan, INC. | $1,210.52 | 2019-2022 | |
| Lundbeck LLC | $1,161.16 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,062.02 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Novartis Pharmaceuticals Corporation | $935.22 | 2019-2025 | |
| Lilly USA, LLC | $769.56 | 2019-2024 | Amyvid, Reyvow, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $741.28 | 2019-2025 | Trintellix, Hyqvia |
| Scilex Pharmaceuticals INC. | $713.14 | 2020-2025 | Ztlido |
| Arbor Pharmaceuticals, INC. | $558.77 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $547.61 | 2019-2023 | Ingrezza, Ongentys |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Neystat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.